Naumaan Hafeez, MD
Internal Medicine · Sun City Center, FLNPI 1194214502
Payments from drug & device makers
Across 89 payments — averaging $25.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$398
- Otsuka America Pharmaceutical, Inc.$219
- Amgen$149
- Exact Sciences$141
- Lilly USA, LLC$131
- UCB, Inc.$125
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,289100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $398 |
| Otsuka America Pharmaceutical, Inc. | 5 | $219 |
| Amgen | 8 | $149 |
| Exact Sciences | 6 | $141 |
| Lilly USA, LLC | 7 | $131 |
| UCB, Inc. | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $124 |
| Sumitomo Pharma America, Inc. | 7 | $120 |
| Boston Scientific | 2 | $109 |
| Silk Road Medical, Inc. | 1 | $92 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $87 |
| Astellas Pharma US Inc | 3 | $76 |
| AstraZeneca | 4 | $68 |
| Pfizer | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 3 | $54 |
| Lundbeck LLC | 3 | $45 |
| Novo Nordisk | 2 | $38 |
| GSK | 2 | $29 |
| Merck | 1 | $26 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Microtransponder, Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Averitas Pharma Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Curonix LLC | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Johnson & Johnson | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Briviact$125
- INJECTAFER$124
- REXULTI$122
- UBRELVY$102
How this compares
$2,289 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 91 | $96,630 |
| JardianceEmpagliflozin | 56 | $45,893 |
| MounjaroTirzepatide | 25 | $37,293 |
| XareltoRivaroxaban | 33 | $28,042 |
| FarxigaDapagliflozin Propanediol | 26 | $21,844 |
| MyrbetriqMirabegron | 36 | $18,767 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 31 | $15,829 |
| OzempicSemaglutide | 13 | $12,581 |
| JanuviaSitagliptin Phosphate | 25 | $10,218 |
| Levemir FlexpenInsulin Detemir | 24 | $3,642 |
| Atorvastatin Calcium | 273 | $3,618 |
| Gabapentin | 193 | $3,216 |
| Rosuvastatin Calcium | 107 | $2,322 |
| Sertraline Hcl | 107 | $2,250 |
| Omeprazole | 100 | $2,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59 | $96,63091 claims |
| Boehringer IngelheimJardiance | $20 | $45,89356 claims |
| Lilly USA, LLCMounjaro | $131 | $37,29325 claims |
| Johnson & JohnsonXarelto | $14 | $28,04233 claims |
| AstraZenecaFarxiga | $68 | $21,84426 claims |
| Astellas Pharma US IncMyrbetriq | $76 | $18,76736 claims |
| GSKTrelegy Ellipta | $29 | $15,82931 claims |
| Novo NordiskOzempic | $38 | $12,58113 claims |
| MerckJanuvia | $26 | $10,21825 claims |
| AbbVieSynthroid | $398 | $1,95630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Sun City Center
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.